EHang Holdings Ltd - ADR vs Revvity Inc — how do they compare? EHang Holdings Ltd - ADR trades at $4.19 (market cap $309.45M), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 54.9× EHang Holdings Ltd - ADR's market cap, and Revvity Inc pays a 0.18% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 47 Days and Revvity Inc for 12 Days on average.
| EH | RVTY | |
|---|---|---|
Market Cap | $309.45M | $16.98B |
Volume | 765,799 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $18.94 | $157.36 |
52-Week Low | $4.03 | $82.26 |
Typical Hold Time | 47 Days | 12 Days |
Enterprise Value | $261.14M | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $4.08, down 1.45% on the day, with a bearish technical signal driven by moving averages. The company reported revenue of $418 million in 2025 but posted a net loss of $276 million, with negative profitability margins and a P/S ratio of 5.38. Recent news highlights regulatory investigations and expansion of its eVTOL program in Vietnam, creating mixed sentiment amid operational progress and legal scrutiny.
The outlook remains challenged by persistent losses and high cash burn, though expansion initiatives offer long-term potential. Key risks include regulatory hurdles, competitive pressures, and reliance on financing. Analyst consensus is divided, with 20% buy ratings, reflecting cautious optimism balanced against fundamental weaknesses.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →